Squarepoint’s IO Biotech IOBT Stock Holding History

Squarepoint’s Portfolio IOBT Stock Details IOBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-14,966	Closed	-$98K	–	3172
2021 Q4	$98K	Buy	+14,966	New	+$145K	﹤0.01%	2921

Other funds holding IOBT

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Squarepoint's IOBT Position: Q1 2022 in Review

Squarepoint sold out of IO Biotech (IOBT) in Q1 2022, closing a stake of 14,966 shares — an estimated $98K sold.

Squarepoint first reported a position in IOBT in Q4 2021 and held it in 1 quarter. The position peaked at $98K in Q4 2021. 19 funds tracked by Wall St. Rank hold IOBT as of Q1 2022.

Squarepoint reported no remaining IO Biotech position as of Q1 2022 after selling out during the quarter.
Squarepoint sold 14,966 IO Biotech shares in Q1 2022, an estimated $98K.
Squarepoint first reported a position in IO Biotech in Q4 2021 and held it in 1 quarter.
Squarepoint's IO Biotech position peaked at $98K in Q4 2021.
19 funds tracked by Wall St. Rank held IO Biotech as of Q1 2022.

Based on Squarepoint's 13F filing for Q1 2022, filed 16 May 2022.